Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma

Background: Although TP53 co-mutation with KRAS/ATM/EGFR/STK11 have been proved to have predictive value for response to immune checkpoint inhibitors (ICIs), not all TP53 mutations are equal in this context. As the main part of TP53 mutant types, Missense and Nonsense alternations in TP53 as indepen...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Hao Sun, Si-Yang Liu, Jia-Ying Zhou, Jin-Tian Xu, Huang-Kai Zhang, Hong-Hong Yan, Jiao-Jiao Huan, Ping-Ping Dai, Chong-Rui Xu, Jian Su, Yan-Fang Guan, Xin Yi, Rong-Shan Yu, Wen-Zhao Zhong, Yi-Long Wu
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Elsevier 2020-10-01
سلاسل:	EBioMedicine
الموضوعات:	TP53 Lung adenocarcinoma Immunotherapy Subtypes
الوصول للمادة أونلاين:	http://www.sciencedirect.com/science/article/pii/S2352396420303662
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!